The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
 
Michael J. Morris
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Blue Earth Diagnostics; Endocyte; ORIC Pharmaceuticals; Tokai Pharmaceuticals; Tolmar
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Endocyte
 
Lawrence Fong
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; GlaxoSmithKline; Lilly; PSMA Therapeutics; United Health Group; Varian Medical Systems
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Myovant Sciences; Myriad Genetics; Novartis; Novartis; Noxopharm; Pfizer; Progenics; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck (Inst); Sanofi (Inst); SOTIO
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Celestia S. Higano
Honoraria - Astellas Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Clovis Oncology; Ferring; Ferring; Hinova Pharmaceuticals; Hinova Pharmaceuticals; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Emergent BioSolutions (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Carrick Therapeutics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer
 
Lance C. Pagliaro
Research Funding - Exelixis (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
Other Relationship - Pfizer
 
Winston Tan
Honoraria - Medscape
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Raphaelle Porcu
Employment - F. Hoffmann LaRoche
 
Darren Tayama
Employment - Genentech
 
Edward Ernest Kadel
Employment - Genentech/Roche
Stock and Other Ownership Interests - Celgene; Clinuvel; Compugen; Epizyme; Genentech/Roche; Gilead Sciences; Gilead Sciences (I); Mannkind; Merck; Vertex
Travel, Accommodations, Expenses - Genentech/Roche
 
Kobe Chi Yung Yuen
Employment - Genentech
 
Asim Datye
Employment - F. Hoffmann LaRoche
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech